Drug Shortage Report for EXELON
| Report ID | 265891 |
| Drug Identification Number | 02245240 |
| Brand name | EXELON |
| Common or Proper name | RIVASTIGMINE |
| Company Name | KNIGHT THERAPEUTICS INC. |
| Market Status | MARKETED |
| Active Ingredient(s) | RIVASTIGMINE |
| Strength(s) | 2MG |
| Dosage form(s) | SOLUTION |
| Route of administration | ORAL ORAL |
| Packaging size | All sizes |
| ATC code | N06DA |
| ATC description | ANTI-DEMENTIA DRUGS |
| Reason for shortage | Demand increase for the drug. |
| Anticipated start date | 2025-08-25 |
| Actual start date | 2025-08-25 |
| Estimated end date | 2025-10-31 |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2025-10-07 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 100 ALEXIS-NIHON BLVD., SUITE 600 MONTREAL, QUEBEC CANADA H4M 2P2 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2025-10-07 | French | Compare |
| v4 | 2025-10-07 | English | Compare |
| v3 | 2025-08-26 | English | Compare |
| v2 | 2025-08-25 | French | Compare |
| v1 | 2025-08-25 | English | Compare |
Showing 1 to 5 of 5